세계의 단일세포 분석 시장 : 용도별, 세포 유형별, 최종사용자별, 제품별, 방법별, 지역별 - 예측(-2030년)

The single-cell analysis market is projected to reach USD 7.56 billion by 2030 from an estimated USD 3.81 billion in 2025, at a CAGR of 14.7% during the forecast period. This market growth is largely driven by the increasing emphasis on personalized medicine. Rising research & development investments in the pharmaceutical and biotechnology industries also contribute to the expansion of single-cell analysis. Additionally, factors such as growth in stem cell research and advancements in single-cell analysis technologies are expected to further boost the market. Furthermore, the increasing incidence of cancer is creating a demand for advanced therapies, which is anticipated to enhance the growth of the single-cell analysis market. The rising adoption of advanced single-cell sequencing techniques is also expected to propel market growth in the coming years.

"The research applications segment accounted for the largest share of the market segment in 2024."

The single-cell analysis market is divided into two main categories based on applications: research and medical applications. The research application segment includes various fields such as cancer research, immunology research, neurology research, stem cell research, and other related areas. In contrast, the medical applications segment is further divided into non-invasive prenatal diagnosis, in vitro fertilization, and circulating tumor cell detection.

In 2024, the research applications segment held the largest share of the global single-cell analysis market. The increasing prevalence of cancer is driving the demand for advanced therapies, which contributes to the growth of this segment. Additionally, the expansion of stem cell research is also expected to further boost the growth of the single-cell analysis market.

"The flow cytometry segment accounted for a major share of the market in 2024."

The single-cell analysis market is categorized based on technology into several segments: flow cytometry, next-generation sequencing, polymerase chain reaction, microscopy, mass spectrometry, and other techniques. In 2024, the flow cytometry segment was the largest contributor to the global single-cell analysis market by technology. This significant growth is primarily due to the widespread use of flow cytometry in single-cell analysis, as it can perform multiple measurements within a heterogeneous mixture. Furthermore, the increasing adoption of advanced cell identification and characterization technologies is expected to further drive growth in this segment of the single-cell analysis market.

"The US dominated the single-cell analysis market in 2024."

The single-cell analysis market is divided into six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2024, the US dominated this market in North America. As the world's largest biopharmaceutical market, the US leads in biopharmaceutical research and investments. Its robust healthcare infrastructure further supports research & development in the life sciences sector. Additionally, the presence of numerous biopharmaceutical companies and increasing research activities in the biotechnology industry are contributing to market growth in the US. Furthermore, the rising focus on developing personalized medicine, driven by the increasing incidence of cancer, is also boosting the growth of the single-cell analysis market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side (70%) and Demand Side (30%)
• By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
• By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and Middle East & Africa (5%)

List of Companies Profiled in the Report:

• Thermo Fisher Scientific Inc. (US)
• Danaher Corporation (US)
• Merck KGaA (Germany)
• BD (US)
• Agilent Technologies, Inc. (US)
• QIAGEN (Netherlands)
• 10x Genomics (US)
• Illumina, Inc. (US)
• Bio-Rad Laboratories, Inc. (US)
• DiaSorin S.p.A. (Italy)
• Standard BioTools (US)
• Tecan Trading AG (Switzerland)
• Sartorius AG (Germany)
• Corning Incorporated (US)
• Cytek Biosciences (US)
• Takara Bio Inc. (Japan)
• bioMerieux (France)
• Revvity (US)
• Bio-Techne (US)
• PacBio (US)
• Bruker (US)
• Promega Corporation (US)
• Oxford Nanopore Technologies plc. (UK)
• The Menarini Group (Italy)
• Singleron Biotechnologies (Germany)
• BICO (Sweden)
• Fluent BioSciences (US)
• RareCyte, Inc. (US)
• Cell Microsystems (US)
• NanoCellect Biomedical (US)
• Apogee Flow Systems Ltd. (UK)
• Creative Biolabs (US)
• Sphere Bio (UK)
• Yokogawa Electric Corporation (Japan)

Research Coverage:

This research report categorizes the single-cell analysis market by product {consumables [reagents, assay kits (immunoassays and cell-based assays), beads, microplates, and other consumables] and instruments (PCR instruments, NGS systems, flow cytometers, spectrophotometers, cell counters, microscopes, HCS systems, microarrays, and other instruments)}, cell type (human cells, animal cells, and microbial cells), technique (flow cytometry, next-generation sequencing, microscopy, polymerase chain reaction, mass spectrometry, and other techniques), application [research applications (cancer research, immunology research, neurology research, stem cell research, and other research applications) and medical applications (non-invasive prenatal diagnosis, in vitro fertilization, and circulating tumour cell detection)], end user (academic & research laboratories, biotechnology & pharmaceutical companies, hospitals & diagnostic laboratories, and cell banks & IVF centers), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the single-cell analysis market. A thorough analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. Also, it includes new product launches, collaborations, acquisitions, and recent developments associated with the single-cell analysis market.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the overall single-cell analysis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (technological advancements in single-cell analysis products, the surge in cases of cancer, and increasing R&D in pharmaceutical & biotechnology industries for complex diseases), restraints (high cost of single-cell analysis products), opportunities (integration of microfluidics in single-cell analysis), and challenges (standardization of protocols and data integration & quality control for developing cell therapies) influencing the growth of the market
• Product Development/Innovation: Detailed insights on newly launched products of the single-cell analysis market
• Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the single-cell analysis market
• Competitive Assessment: Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), BD (US), Agilent Technologies, Inc. (US), QIAGEN (Netherlands), 10x Genomics (US), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), DiaSorin S.p.A. (Italy), Standard BioTools (US), Tecan Trading AG (Switzerland), Sartorius AG (Germany), Corning Incorporated (US), Cytek Biosciences (US), Takara Bio Inc. (Japan), bioMerieux (France), Revvity (US), Bio-Techne (US), PacBio (US), Bruker (US), Promega Corporation (US), Oxford Nanopore Technologies plc. (UK), The Menarini Group (Italy), Singleron Biotechnologies (Germany), BICO (Sweden), Fluent BioSciences (US), RareCyte, Inc. (US), Cell Microsystems (US), NanoCellect Biomedical (US), Apogee Flow Systems Ltd. (UK), Creative Biolabs (US) Sphere Bio (UK), and Yokogawa Electric Corporation (Japan)

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
  • 1.3.2 YEARS CONSIDERED
  • 1.3.3 INCLUSIONS AND EXCLUSIONS
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET SIZE ESTIMATION METHODOLOGY
  • 2.2.1 GLOBAL SINGLE-CELL ANALYSIS MARKET SIZE ESTIMATION
  • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
  • 2.2.3 TOP-DOWN APPROACH
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RISK ANALYSIS
• 2.7 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN SINGLE-CELL ANALYSIS MARKET
• 4.2 NORTH AMERICA: SINGLE-CELL ANALYSIS MARKET, BY CELL TYPE AND COUNTRY
• 4.3 SINGLE-CELL ANALYSIS MARKET, BY PRODUCT, 2025 VS. 2030
• 4.4 SINGLE-CELL ANALYSIS MARKET, BY END USER
• 4.5 SINGLE-CELL ANALYSIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Technological advancements in single-cell analysis products
    • 5.2.1.2 Rising prevalence of cancer
    • 5.2.1.3 Increasing R&D in pharmaceutical and biotechnology industries
    • 5.2.1.4 Growth in stem cell research
    • 5.2.1.5 Growing focus on personalized medicine
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of single-cell analysis products
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 High growth potential of single-cell sequencing
    • 5.2.3.2 Integration of microfluidics in single-cell analysis
    • 5.2.3.3 Rising potential in emerging Asian markets
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Lack of standardization in protocols and quality control procedures
    • 5.2.4.2 Technical limitations of single-cell analysis
    • 5.2.4.3 Mounting ethical and privacy concerns
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 TECHNOLOGY ANALYSIS
  • 5.6.1 KEY TECHNOLOGIES
    • 5.6.1.1 Flow cytometry
    • 5.6.1.2 Next-generation sequencing
    • 5.6.1.3 Polymerase chain reaction
    • 5.6.1.4 Microscopy
    • 5.6.1.5 Mass spectrometry
  • 5.6.2 COMPLEMENTARY TECHNOLOGIES
    • 5.6.2.1 Bioinformatics tools and computational analysis
    • 5.6.2.2 Multi-omics integration
  • 5.6.3 ADJACENT TECHNOLOGIES
    • 5.6.3.1 Nanotechnology
    • 5.6.3.2 Artificial intelligence and machine learning
• 5.7 PATENT ANALYSIS
  • 5.7.1 METHODOLOGY
  • 5.7.2 PATENTS APPLIED AND GRANTED, 2014-2024
• 5.8 TRADE ANALYSIS
  • 5.8.1 IMPORT DATA (HS CODE 9027)
  • 5.8.2 EXPORT DATA (HS CODE 9027)
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 THREAT OF NEW ENTRANTS
  • 5.9.2 THREAT OF SUBSTITUTES
  • 5.9.3 BARGAINING POWER OF SUPPLIERS
  • 5.9.4 BARGAINING POWER OF BUYERS
  • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.10 TARIFF & REGULATORY LANDSCAPE
  • 5.10.1 TARIFF DATA (HS CODE 9027)
  • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10.3 REGULATORY FRAMEWORK
• 5.11 PRICING ANALYSIS
  • 5.11.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYERS
  • 5.11.2 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION
• 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.13.2 ROLE OF STAKEHOLDERS IN BUYING PROCESS
  • 5.13.3 BUYING CRITERIA
• 5.14 INVESTMENT AND FUNDING SCENARIO
• 5.15 IMPACT OF GENERATIVE AI ON SINGLE-CELL ANALYSIS MARKET
  • 5.15.1 AI USE-CASES
  • 5.15.2 KEY COMPANIES IMPLEMENTING AI
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 COMPREHENSIVE SINGLE-CELL TRANSCRIPTOMIC ATLAS OF HUMAN CORNEA
  • 5.16.2 MASSIVELY PARALLEL SINGLE-CELL RNA SEQUENCING IDENTIFIES RARE DRUG-RESISTANT CANCER SUBPOPULATIONS
  • 5.16.3 SINGLE-CELL ANALYSIS OF RENAL CELL CARCINOMA REVEALS TUMOR HETEROGENEITY AND MICROENVIRONMENTAL COMPLEXITY
• 5.17 US 2025 TARIFF IMPACT OVERVIEW
  • 5.17.1 INTRODUCTION
  • 5.17.2 KEY TARIFF RATES
  • 5.17.3 PRICE IMPACT ANALYSIS
  • 5.17.4 KEY IMPACT ON VARIOUS REGIONS
    • 5.17.4.1 US
    • 5.17.4.2 Europe
    • 5.17.4.3 Asia Pacific
    • 5.17.4.4 Rest of the World
  • 5.17.5 END-USE INDUSTRY IMPACT
    • 5.17.5.1 Pharmaceutical and biotech companies
    • 5.17.5.2 Contract research organizations (CROs)
    • 5.17.5.3 Academic & research institutes

6 SINGLE-CELL ANALYSIS MARKET, BY APPLICATION

• 6.1 INTRODUCTION
• 6.2 RESEARCH APPLICATIONS
  • 6.2.1 CANCER RESEARCH
    • 6.2.1.1 Rising prevalence of cancer to drive market
  • 6.2.2 IMMUNOLOGY RESEARCH
    • 6.2.2.1 High incidence of immunological disorders to propel market
  • 6.2.3 NEUROLOGY RESEARCH
    • 6.2.3.1 Increasing incidence of neurological disorders to boost market
  • 6.2.4 STEM CELL RESEARCH
    • 6.2.4.1 Rising investments in stem cell research to drive market
  • 6.2.5 OTHER RESEARCH APPLICATIONS
• 6.3 MEDICAL APPLICATIONS
  • 6.3.1 NON-INVASIVE PRENATAL DIAGNOSIS
    • 6.3.1.1 Increasing prevalence of genetic diseases to drive demand
  • 6.3.2 IN VITRO FERTILIZATION
    • 6.3.2.1 Growing demand for IVF procedures to support market
  • 6.3.3 CIRCULATING TUMOR CELL DETECTION
    • 6.3.3.1 Rising prevalence of cancer to contribute to segment growth

7 SINGLE-CELL ANALYSIS MARKET, BY CELL TYPE

• 7.1 INTRODUCTION
• 7.2 HUMAN CELLS
  • 7.2.1 GROWING FUNDING FOR CANCER RESEARCH TO BOOST DEMAND
• 7.3 ANIMAL CELLS
  • 7.3.1 INCREASING ANIMAL CELL RESEARCH TO DRIVE MARKET
• 7.4 MICROBIAL CELLS
  • 7.4.1 RISING GOVERNMENT SUPPORT TO COMBAT ANTIMICROBIAL RESISTANCE TO PROPEL MARKET

8 SINGLE-CELL ANALYSIS MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 ACADEMIC & RESEARCH LABORATORIES
  • 8.2.1 INCREASING FUNDING FOR LIFE SCIENCE RESEARCH TO DRIVE MARKET
• 8.3 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES
  • 8.3.1 GROWTH IN DRUG DISCOVERY AND R&D ACTIVITIES TO BOOST MARKET
• 8.4 HOSPITALS & DIAGNOSTIC LABORATORIES
  • 8.4.1 HIGH PREVALENCE OF INFECTIOUS AND CHRONIC DISEASES TO DRIVE DEMAND
• 8.5 CELL BANKS & IVF CENTERS
  • 8.5.1 RISING DEMAND FOR PERSONALIZED AND REGENERATIVE MEDICINE TO PROPEL MARKET

9 SINGLE-CELL ANALYSIS MARKET, BY PRODUCT

• 9.1 INTRODUCTION
• 9.2 CONSUMABLES
  • 9.2.1 BEADS
    • 9.2.1.1 Increasing use in research and genetic exploration to drive market
  • 9.2.2 MICROPLATES
    • 9.2.2.1 Rising frequency of product launches to boost market
  • 9.2.3 REAGENTS
    • 9.2.3.1 Advancements in single-cell genomics to increase demand
  • 9.2.4 ASSAY KITS
    • 9.2.4.1 Immunoassays
      • 9.2.4.1.1 Growth in geriatric population to fuel demand
    • 9.2.4.2 Cell-based assays
      • 9.2.4.2.1 Increasing use in pharma and biopharma companies to drive market
  • 9.2.5 OTHER CONSUMABLES
• 9.3 INSTRUMENTS
  • 9.3.1 FLOW CYTOMETERS
    • 9.3.1.1 Technological advancements to drive demand
  • 9.3.2 NGS SYSTEMS
    • 9.3.2.1 Increased affordability to support segment growth
  • 9.3.3 PCR INSTRUMENTS
    • 9.3.3.1 Rising use for DNA and mRNA amplification to boost market
  • 9.3.4 SPECTROPHOTOMETERS
    • 9.3.4.1 Technological advancements to boost market
  • 9.3.5 CELL COUNTERS
    • 9.3.5.1 Rising demand for automated cell counters to fuel market
  • 9.3.6 MICROSCOPES
    • 9.3.6.1 Increasing use in cell-based research to drive market
  • 9.3.7 HCS SYSTEMS
    • 9.3.7.1 Growing need for multi-parametric cell analysis to drive adoption
  • 9.3.8 MICROARRAYS
    • 9.3.8.1 Increasing development of targeted therapies to support market
  • 9.3.9 OTHER INSTRUMENTS

10 SINGLE-CELL ANALYSIS MARKET, BY TECHNIQUE

• 10.1 INTRODUCTION
• 10.2 FLOW CYTOMETRY
  • 10.2.1 INCREASING USE TO IDENTIFY CANCEROUS CELLS TO DRIVE MARKET
• 10.3 NEXT-GENERATION SEQUENCING
  • 10.3.1 WIDE ADOPTION IN DRUG DISCOVERY TO DRIVE MARKET
• 10.4 POLYMERASE CHAIN REACTION
  • 10.4.1 INCREASING APPLICATIONS OF DIGITAL PCR TO SUPPORT MARKET
• 10.5 MICROSCOPY
  • 10.5.1 FOCUS ON DEVELOPMENT OF ADVANCED IMAGING SYSTEMS TO PROPEL MARKET
• 10.6 MASS SPECTROMETRY
  • 10.6.1 LAUNCH OF ADVANCED PRODUCTS TO DRIVE MARKET
• 10.7 OTHER TECHNIQUES

11 SINGLE-CELL ANALYSIS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Increasing R&D investments and funding to drive market
  • 11.2.3 CANADA
    • 11.2.3.1 High prevalence of hemophilia to propel market
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Growing awareness of advanced cell therapies to support market
  • 11.3.3 UK
    • 11.3.3.1 Growing adoption of single-cell analysis products to drive demand
  • 11.3.4 FRANCE
    • 11.3.4.1 Growing government funding for R&D to propel market
  • 11.3.5 ITALY
    • 11.3.5.1 Focus on cell biology research to drive market
  • 11.3.6 SPAIN
    • 11.3.6.1 Increasing number of biotechnology companies to drive demand
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Increasing R&D expenditure to support market
  • 11.4.3 JAPAN
    • 11.4.3.1 Increasing geriatric population to fuel demand
  • 11.4.4 INDIA
    • 11.4.4.1 Growing focus on development of cell-based therapies to boost market
  • 11.4.5 SOUTH KOREA
    • 11.4.5.1 Increasing number of strategic alliances to boost market
  • 11.4.6 AUSTRALIA
    • 11.4.6.1 Rising number of life science companies to boost demand
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Rising focus on biotechnology industry to bolster market
  • 11.5.3 MEXICO
    • 11.5.3.1 Government support for biopharmaceutical production to drive market
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST
  • 11.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST
  • 11.6.2 GCC
    • 11.6.2.1 Saudi Arabia
      • 11.6.2.1.1 Increasing healthcare expenditure to drive market
    • 11.6.2.2 United Arab Emirates
      • 11.6.2.2.1 Advancements in biopharmaceutical sector to drive demand
    • 11.6.2.3 Rest of GCC
  • 11.6.3 REST OF MIDDLE EAST
• 11.7 AFRICA
  • 11.7.1 GROWING FUNDING FOR DEVELOPMENT AND PRODUCTION OF BIOPHARMACEUTICALS TO DRIVE MARKET
  • 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021-2025
• 12.3 REVENUE ANALYSIS, 2022-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
  • 12.4.1 RANKING OF KEY MARKET PLAYERS
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Product footprint
    • 12.5.5.3 Region footprint
    • 12.5.5.4 Technique footprint
    • 12.5.5.5 Application footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 12.6.5.1 Detailed list of key startups/SMEs
    • 12.6.5.2 Competitive benchmarking of key startups/SMEs
• 12.7 COMPANY VALUATION AND FINANCIAL METRICS
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 INTRODUCTION
• 13.2 KEY PLAYERS
  • 13.2.1 BD
    • 13.2.1.1 Business overview
    • 13.2.1.2 Products offered
    • 13.2.1.3 Recent developments
      • 13.2.1.3.1 Product launches
      • 13.2.1.3.2 Deals
    • 13.2.1.4 MnM view
      • 13.2.1.4.1 Key strengths
      • 13.2.1.4.2 Strategic choices
      • 13.2.1.4.3 Weaknesses and competitive threats
  • 13.2.2 THERMO FISHER SCIENTIFIC INC.
    • 13.2.2.1 Business overview
    • 13.2.2.2 Products offered
    • 13.2.2.3 Recent developments
      • 13.2.2.3.1 Product launches
      • 13.2.2.3.2 Deals
    • 13.2.2.4 MnM view
      • 13.2.2.4.1 Key strengths
      • 13.2.2.4.2 Strategic choices
      • 13.2.2.4.3 Weaknesses and competitive threats
  • 13.2.3 DANAHER CORPORATION
    • 13.2.3.1 Business overview
    • 13.2.3.2 Products offered
    • 13.2.3.3 Recent developments
      • 13.2.3.3.1 Deals
    • 13.2.3.4 MnM view
      • 13.2.3.4.1 Key strengths
      • 13.2.3.4.2 Strategic choices
      • 13.2.3.4.3 Weaknesses and competitive threats
  • 13.2.4 10X GENOMICS
    • 13.2.4.1 Business overview
    • 13.2.4.2 Products offered
    • 13.2.4.3 Recent developments
      • 13.2.4.3.1 Product launches
      • 13.2.4.3.2 Deals
  • 13.2.5 MERCK KGAA
    • 13.2.5.1 Business overview
    • 13.2.5.2 Products offered
    • 13.2.5.3 Recent developments
      • 13.2.5.3.1 Deals
  • 13.2.6 AGILENT TECHNOLOGIES, INC.
    • 13.2.6.1 Business overview
    • 13.2.6.2 Products offered
    • 13.2.6.3 Recent developments
      • 13.2.6.3.1 Product launches
      • 13.2.6.3.2 Deals
  • 13.2.7 QIAGEN
    • 13.2.7.1 Business overview
    • 13.2.7.2 Products offered
    • 13.2.7.3 Recent developments
      • 13.2.7.3.1 Deals
  • 13.2.8 ILLUMINA, INC.
    • 13.2.8.1 Business overview
    • 13.2.8.2 Products offered
    • 13.2.8.3 Recent developments
      • 13.2.8.3.1 Product launches
      • 13.2.8.3.2 Deals
  • 13.2.9 BIO-RAD LABORATORIES, INC.
    • 13.2.9.1 Business overview
    • 13.2.9.2 Products offered
    • 13.2.9.3 Recent developments
      • 13.2.9.3.1 Product launches
  • 13.2.10 DIASORIN S.P.A.
    • 13.2.10.1 Business overview
    • 13.2.10.2 Products offered
    • 13.2.10.3 Recent developments
      • 13.2.10.3.1 Deals
  • 13.2.11 STANDARD BIOTOOLS
    • 13.2.11.1 Business overview
    • 13.2.11.2 Product offered
    • 13.2.11.3 Recent developments
      • 13.2.11.3.1 Product launches
      • 13.2.11.3.2 Deals
  • 13.2.12 TECAN TRADING AG
    • 13.2.12.1 Business overview
    • 13.2.12.2 Products offered
    • 13.2.12.3 Recent developments
      • 13.2.12.3.1 Product launches
      • 13.2.12.3.2 Deals
  • 13.2.13 SARTORIUS AG
    • 13.2.13.1 Business overview
    • 13.2.13.2 Products offered
    • 13.2.13.3 Recent developments
      • 13.2.13.3.1 Deals
      • 13.2.13.3.2 Expansions
  • 13.2.14 CORNING INCORPORATED
    • 13.2.14.1 Business overview
    • 13.2.14.2 Products offered
  • 13.2.15 CYTEK BIOSCIENCES
    • 13.2.15.1 Business overview
    • 13.2.15.2 Products offered
    • 13.2.15.3 Recent developments
      • 13.2.15.3.1 Product launches
      • 13.2.15.3.2 Deals
      • 13.2.15.3.3 Expansions
  • 13.2.16 TAKARA BIO INC.
    • 13.2.16.1 Business overview
    • 13.2.16.2 Products offered
    • 13.2.16.3 Recent developments
      • 13.2.16.3.1 Product launches
      • 13.2.16.3.2 Deals
  • 13.2.17 BIOMERIEUX
    • 13.2.17.1 Business overview
    • 13.2.17.2 Products offered
    • 13.2.17.3 Recent developments
      • 13.2.17.3.1 Deals
  • 13.2.18 REVVITY
    • 13.2.18.1 Business overview
    • 13.2.18.2 Products offered
    • 13.2.18.3 Recent developments
      • 13.2.18.3.1 Deals
  • 13.2.19 BIO-TECHNE
    • 13.2.19.1 Business overview
    • 13.2.19.2 Products offered
    • 13.2.19.3 Recent developments
      • 13.2.19.3.1 Deals
  • 13.2.20 PACBIO
    • 13.2.20.1 Business overview
    • 13.2.20.2 Products offered
    • 13.2.20.3 Recent developments
      • 13.2.20.3.1 Product launches
  • 13.2.21 BRUKER
    • 13.2.21.1 Business overview
    • 13.2.21.2 Products offered
    • 13.2.21.3 Recent developments
      • 13.2.21.3.1 Product launches
      • 13.2.21.3.2 Deals
  • 13.2.22 PROMEGA CORPORATION
    • 13.2.22.1 Business overview
    • 13.2.22.2 Products offered
  • 13.2.23 OXFORD NANOPORE TECHNOLOGIES PLC
    • 13.2.23.1 Business overview
    • 13.2.23.2 Products offered
    • 13.2.23.3 Recent developments
      • 13.2.23.3.1 Deals
• 13.3 OTHER PLAYERS
  • 13.3.1 SINGLERON BIOTECHNOLOGIES
  • 13.3.2 CELL MICROSYSTEMS
  • 13.3.3 NANOCELLECT BIOMEDICAL
  • 13.3.4 RARECYTE, INC.
  • 13.3.5 BICO
  • 13.3.6 MENARINI GROUP
  • 13.3.7 APOGEE FLOW SYSTEMS LTD
  • 13.3.8 CREATIVE BIOLABS
  • 13.3.9 SPHERE BIO
  • 13.3.10 YOKOGAWA ELECTRIC CORPORATION

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS